AUCTORES
Globalize your Research
Review | DOI: https://doi.org/10.31579/2768-0487/193
Interdisciplinary researcher of the International Academy of Education, Technological Platform MEDICINE OF THE FUTUR, Russia, Novosibirsk.
*Corresponding Author: Evgenii Brindin., Interdisciplinary researcher of the International Academy of Education, Technological Platform MEDICINE OF THE FUTUR, Russia, Novosibirsk.
Citation: Evgenii Brindin, (2025), Hormonal Genetic Synergy-Induced Regression of Prostate Adenocarcinoma, Journal of Clinical and Laboratory Research, 8(5); DOI:10.31579/2768-0487/193
Copyright: © 2025, Evgenii Brindin. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 24 October 2025 | Accepted: 10 November 2025 | Published: 24 November 2025
Keywords: hormonal genetic synergy; induced regression; prostate adenocarcinoma
Hormonal therapy is the standard treatment for advanced androgen-dependent prostate adenocarcinoma. If tumor regression is not achieved early, the adenocarcinoma inevitably evolves toward androgen independence. This is due to the development of resistance mechanisms and the incomplete tissue-level cessation of androgen deprivation. Current research is focused on combined therapeutic strategies that will increase the effectiveness of androgen deprivation and delay recurrence. Androgen deprivation through hormonal therapy combined with genetic therapy can induce tumor regression by reducing angiogenesis and enhancing mitotic arrest and apoptosis. A study by the Intergroup in the United States has demonstrated a method for hormonal and genetic restoration of altered prostate cancer patterns resulting from intergenic suppression. This is due to mutations that alter the process by which the genetic information of a mutated gene is expressed. This highlights the urgent need to combine hormonal and genetic therapeutic approaches and expand our current understanding of molecular mechanisms. Epigenetic changes are considered key factors in prostate cancer treatment. Studies have shown that targeting epigenetic enzymes or regulatory proteins halts cancer cell division. Combining hormonal and genetic therapeutic approaches leads to induced regression of prostate adenocarcinoma.
The development of prostate adenocarcinoma depends on hormones, so controlling them can slow or stop the growth of tumors. Hormone therapy is considered systemic because the substances used are distributed throughout the body. This distinguishes it from local treatments such as radiation or surgery, which target only a specific area. Oral hormonal therapy medications are taken orally as tablets, capsules, or liquids. This can be done at home, following a specific regimen prescribed by a doctor. Some medications are available as injections, administered into the arm, leg, thigh, or under the skin of the abdomen. Hormonal therapy for prostate cancer involves reducing levels of androgens—male hormones that stimulate tumor cell growth. The main types—testosterone and dihydrotestosterone—are produced by the testicles and adrenal glands. The adrenal glands are glands located above each kidney and produce hormones that help the body respond to stress, strain, and environmental changes. This hormone is also important for prostate cancer itself. Reducing the levels of these substances or preventing their entry into abnormal cells leads to tumor shrinkage or slowing of their growth. Drugs that lower hormone levels to a safe level include leuprolide (Lupron, Eligard), goserelin (Zoladex), triptorelin, histrelin, leuprolide mesylate, degarelix (Firmagon), and relugolix (Orgovix). Ketoconazole (Nizoral) is used to treat patients diagnosed with prostate cancer. Newer agents with similar effects—enzalutamide, apalutamide, and darolutamide—are prescribed to men whose cancer has not spread but is unresponsive to other forms of similar therapy. Enzalutamide can also be used for metastatic disease. Genetic therapy for prostate cancer is a treatment based on the manipulation of the genetic material of cancer cells or the patient's immune cells to suppress tumor growth, destroy it, or enhance the effectiveness of hormonal therapy. Key approaches include:
- Tumor gene or nucleic acid delivery: introducing normal or regulatory genes, or donor "suicide" genes (e.g., HSV-TK, followed by the use of profauga), to induce cancer cell death.
- Genome editing: using CRISPR/Cas9 and similar technologies to disable driver oncogenes or correct defects that reduce tumor cell malignancy.
- Oncolytic virus therapy: modified viruses that selectively replicate in cancer cells and cause their death, sometimes in conjunction with the delivery of therapeutic genes.
- Gene immunotherapy: the production of CAR-T cells or other T-cell therapies modified to recognize prostate antigens (e.g., PSMA/PSCA) and enhance the anti-tumor immune response.
- Nucleic acid-based gene vaccines/immunotherapy: vaccines or nanocarriers with mRNA/DNA aimed at activating immunity against cancer cells.
In most countries, genetic therapy for prostate cancer is primarily within the scope of clinical trials and is not combined with hormonal therapy.
This article discusses the combination of hormonal and genetic therapy for induced regression of prostate adenocarcinoma [1-8].
Induced regression of prostate adenocarcinoma is a reduction in tumor size or a decrease in biochemical markers of the disease (e.g., PSA) induced by treatment. Treatment options include:
- Androgen-dependent regression induced by hormonal therapy (ADT): Removal of androgens or blockade of their receptor leads to a reduction in tumor growth and a decrease in PSA. This is a classic example of induced regression in the prostate.
- Chemotherapy: Doxetaxel can induce tumor regression and a decrease in PSA in hormone-sensitive metastatic prostate cancer; the disease may then progress into a resistance crisis.
- Risk/AR pathway inhibitors: abiraterone (creates androgen deprivation therapy), enzalutamide, and apalutamide lead to regression or stabilization of the disease in many patients.
- PARP inhibitors: in patients with BRCA1/2 or myRT (HRR) mutations, they partially induce regression/response to therapy.
- Radiopharmaceuticals and local radiotherapy: radium-223 can reduce symptoms and affect tumor biomass in bone; local radiotherapy/SBRT can lead to regression of individual lesions.
- Immunotherapy: Sipuleucel-T and other approaches can improve survival and sometimes result in regression of individual lesions; often, the effect is expressed not as a sharp reduction in the size of the primary tumor, but as a change in the clinical course.
- Examples of combination strategies: combination hormonal therapy + AR inhibitors, combination therapy with PARP-inHIB, etc.
Assessment of adenocarcinoma regression:
- Biochemical regression: decrease in PSA levels. - Radiographic/magnetic resonance regression according to RECIST 1.1 (for soft tissue lesions); in bone pathology, specific criteria of the Prostate Cancer Working Group (PCWG) and PSMA-pet projects are often used to assess response.
- Clinical symptoms: pain reduction, improved quality of life.
- Regression as a result of therapy is often temporary: after the start of ADT, an initial response often occurs, but resistance may then develop (castration-resistant prostate cancer crisis).
- Specific assessment for bone localization: regression of bone lesions is more difficult to interpret compared to soft tissue tumors.
Let's consider a strategy for activating hormone-induced regression of adenocarcinoma of the prostate (PCa) using hormonal therapy. 1) Objective of the strategy:
- Hormone-sensitive prostate cancer (HSPC): the tumor remains androgen-dependent; removal or strong suppression of the androgen signaling leads to regression or significant disease control. - The goal of hormonal therapy is to maintain castration levels of testosterone and block AR signaling at least until the maximum clinical effect (regression/stabilization) is achieved.
2) Mechanisms of regression under hormonal therapy:
- Suppression of the AR pathway reduces the transcription of counter-regime cellular factors, triggers apoptosis, and cell cycle arrest in hormone-sensitive cells.
- In response, tumor cells can adapt (CRPC) through enhanced AR signaling, intracellular androgen synthesis, AR mutations, or transition to non-estrogen-deficient phenotypes.
3) Clinical strategies for activating regression (main approaches):
- Ensuring castration levels of testosterone:
- Eliminate testosterone below approximately 50 ng/dL (or below 20 ng/dL, which is considered deeper castration) using LHRH antagonists/agents (luteinizing hormone-releasing hormone) or surgical castration.
- LHRH agonists: leuprutide, goserelin, etc.; antagonists: degarelix.
- Combination with AR pathway blockers (intensive antiandrogen approach):
- Antiandrogens: bicalutamide, flutamide, nilutamide - can be used in combination at the start of treatment or to prevent the flare effect.
- Next-generation ARPIs (ARS inhibitors): abiretterone (CYP17A1 inhibitor), enzalutamide, apalutamide - increase the depth of AR signaling suppression in hormonally sensitive stages.
- Intensification of hormonal therapy in localized and locally advanced disease:
- Neoadjuvant hormonal therapy before radiation therapy or surgery in patients with locally advanced or severe disease to reduce tumor bulk.
- In some protocols, disease localization includes a combination of ADT with radiation therapy and/or the addition of ARPI during periods of tumor mobilization.
- Chemotherapy combined with hormonal therapy in patients with mHSPC (metastatic hormone-sensitive PCa):
- Doxetaxel in combination with ADT improves clinical outcomes and may enhance tumor regression early in treatment.
- Growing options within so-called "triplet"/intensive strategies:
- ADT + doxetaxel + ARPI (e.g., abiretterone or an AR inhibitor) in some high-risk patients; data on individual approaches continues to accumulate, and decisions are made on an individual basis.
- Local radiotherapy combined with ADT for oligometastatic disease:
- Used to improve local lesion control and may promote overall tumor regression when combined with castration therapy.
4) Key clinical data and examples of key approaches:
- Meta-analyses and large randomized trials in HSPC show that the combination of ADT with doxetaxel, as well as the early addition of ARPIs (abireterone, enzalutamide, apalutamide), improve overall survival and time to progression compared to ADT alone.
- Examples of large programs:
- LATITUDE: adding abireterone to ADT in patients with metastatic HSPC significantly improves survival.
- TITAN, ARCHES, ENZAMET: demonstrated the benefit of ARPI inhibitors in combination with ADT in the hormonally sensitive metastatic stage.
- CHAARTED, STAMPEDE: adding doxetaxel or other agents to ADT early in treatment improves outcomes. - In the localized stage: neoadjuvant hormonal therapy before local therapy can lead to a reduction in tumor volume and, consequently, more effective disease control.
4. Activation of induced regression of prostate adenocarcinoma by genetic therapy
Activation of induced regression in prostate adenocarcinoma by gene therapy refers to the use of genetic approaches (gene delivery vectors, genome editing, RNA interventions, etc.) to initiate cancer cell death, halt their growth, or enhance the antitumor immune response, leading to tumor regression. This is primarily at the research and clinical trial stages [12-14].
Main strategies (overview by mechanism and status):
- Replacement/introduction of proapoptotic genes:
- Examples: p53, Bax, Bak, Caspases. The goal is to restore or enhance the mechanisms of programmed tumor cell death.
- Delivery formats: adenoviral, lentiviral, ligand carriers, nanotechnology.
- Status: primarily preclinical and early phase clinical trials; some early clinical trials of p53 gene therapy are being conducted in oncology, including research efforts in prostate cancer.
- Suicide gene therapy:
- Example: HSV-tk/ganciclovir—a virally delivered gene modulator that sensitizes cancer cells to drugs and triggers their death.
- Status: Mostly preclinical data, some early clinical trials in combination with local delivery.
- Oncolytic viruses:
- Viruses that preferentially infect and destroy cancer cells, often accompanied by the release of tumor-specific antigens and stimulation of the immune response.
- Application to prostate cancer: Specific vectors (adenoviruses, HSV, etc.) with additional expression of immunomodulators are being investigated. - Status: Clinical trials at various stages, but not standard for this cancer therapy. - Targeted regulation of the AR signaling and related pathways - Approaches: RNAi/siRNA/shRNA or CRISPR to reduce AR activity, AR coactivator inhibitors, editing genes that affect the AR pathway.
- Status: being tested primarily at the preclinical level; some approaches are moving into early clinical trials.
- Regeneration/restoration of tumor suppressor gene function (PTEN, etc.):
- Idea: restore the function of tumor suppressor genes (e.g., PTEN) to slow growth and induce regression.
- Status: primarily preclinical; conceptual and preclinical data available.
- Genetic therapy for immune activation:
- Examples: expression of GM-CSF or other immunomodulators in a genetic vector to enhance antitumor immunity; Potentially, immune cell editing (CAR-T/CRISPR-T) targeting PSMA or other prostate antennae.
- Status: Clinical trials in some formats (combining cell genetic modification and vaccine-like approaches); classic "prostate gene therapy" is still experimental.
- Antiangiogenesis/blood supply inhibition:
- Direct genetic approaches to inhibiting tumor blood vessel growth (e.g., angiostatin/endostatin expression).
- Status: Mainly preclinical data; some approaches are reaching clinical translation as biological agents rather than pure gene therapy.
5) Risks and Limitations:
- Resistance to hormonal therapy (transition to CRPC) through AR mutations, increased intracellular androgen synthesis, AR variants, and other mechanisms.
- Side effects of hormone deprivation: osteoporosis, hyperlipidemia, hypertension, hot flashes, decreased libido/function; interaction with diabetes and cardiovascular risks.
- The regression effect is often partial/temporary; optimal regimens depend on the stage of the disease, the biological profile of the tumor, and the patient's overall health.
6) Monitoring the effectiveness of regression:
- Periodically measure testosterone (target: castration levels) and PSA levels as an early indicator of response.
- Disease imaging (CT/MRI, bone scan) to assess regression or progression. - Monitor toxicity and manage comorbidities.
7) Practical tips for "activating" regression:
- Early and maximal suppression of AR signaling: start with ADT and consider adding ARPI or combination therapies according to an individualized plan.
- Consider combinations of ADT + doxetaxel and/or ARPI in mHSPC in appropriate patients for more in-depth analysis.
- For locally advanced disease, consider neoadjuvant hormonal therapy in conjunction with localized radiotherapy.
- Adopt a long-term control strategy with toxicity minimization: osteoporosis prevention, metabolic monitoring, and prophylactic screening for associated problems.
- Develop differentiated strategies based on the tumor's biological profile (e.g., AR functional variants, potential for tumour loss, somatic mutations, potential for transition to a neuroendocrine phenotype – as data become available) [9-11].
Important information about effects and regression assessment:
- Effects can be local and systemic: tumor regression, PSA reduction, changes on PET/MRI, clinical improvement.
- Regression assessment depends on the methods: RECIST for soft tissue lesions; For prostate and bone pathology, PCWG standards, PSMA-PET, etc. are used.
- Safety and risk: genomic insertion can cause immune responses, inflammation, insertional mutations, and off-target integration into healthy cells; scaling delivery to the prostate is a challenge; strict bioethical and regulatory requirements are required.
5. Genetic therapy for prostate cancer
Genetic therapy for prostate cancer is a set of approaches that utilize tumor genetic information or genetic manipulations to stop cancer cell growth or enhance their destruction. Clinically, the term "gene therapy" is now more commonly used, rather than simply "gene therapy," for therapy tailored to the tumor's genetic profile (genetically targeted therapy). Many genetic methods are in the research and clinical trial stages; other genetically targeted drugs, such as PARP inhibitors, are used for widespread use in most countries if the patient has certain mutations.
Main approaches (overview, without technical details):
- Gene replacement (gene therapy) – delivers normal versions of lost tumor suppressor genes (such as PTEN or p53) or other genes to cancer cells to stop tumor growth. This is primarily a research approach.
- Genome editing (CRISPR/Cas, etc.) – attempts to specifically disable or correct mutations that support cancer growth. Also primarily in clinical trials for now.
- RNA targeting — the use of small RNAs (siRNA/shRNA) or anti-CH oligonucleotides to suppress growth signaling in cancer cells.
- Viral gene therapy and oncolytic viruses — viruses are used as "carriers" to deliver genetic material or directly destroy cancer cells, often stimulating an immune response against the tumor. This is currently in the clinical trials phase.
- Gene immunotherapy (T-cell modification) — the creation of T-lymphocytes targeted to cancer cells (for example, by markers such as PSMA). Also in clinical trials and early-stage treatments. - Tumor-specific genetic therapy (genetically targeted therapy) — for example, PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib, etc.) for patients with mutations in BRCA1/2 or other genes responsible for DNA repair. This is already part of clinical practice, depending on the region and the specific mutation; it is not considered "gene therapy," but directly depends on the tumor's genetic profile.
What this means for prostate cancer:
- Some patients have mutations in BRCA1/2, PALB2, ATM, CHEK2, and other genes associated with DNA repair. PARP inhibitors and other targeted approaches are available for these patients. - Research efforts continue to develop genetic therapy and genome editing in the prostate, including attempts to restore the function of lost genes or alter signaling pathways that control tumor growth. However, at this point in widespread practice, these are most often experimental methods.
- In prostate treatment, genetically based strategies such as PARP inhibitors are most often used, sometimes in combination with hormonal therapy, chemotherapy, or immune therapy, if applicable to the specific mutation.
Pros and cons:
- Advantages: the ability to target specific genetic changes in the tumor, potentially more effective cancer suppression, and the ability to bypass resistance to other therapies.
- Risks and limitations: delivery of genetic material to the desired cells, risk of off-target effects, immune reactions, development complexity and high cost, limited availability of clinical trials. How to determine if a person is suitable:
- Tumor diagnostics and genetic testing (genetic profiling) are required: what mutations are present, whether BRCA1/2 or other DNA repair defects are present. Some patients may be considered for participation in clinical trials of genetic therapies or genome editing.
6. Activation of induced regression of prostate adenocarcinoma by genomic therapy
A strategy for inducing prostate adenocarcinoma regression using genomic therapy involves creating conditions in which prostate cancer cells undergo programmed cell viability decline, apoptosis, or immune-mediated cell death through genetic intervention. This is achieved by suppressing key oncogenic pathways, restoring the function of antitumor genes, and/or stimulating an immune response against the tumor.
The main genomic therapy strategies for inducing regression are:
- Suppression of AR (androgen receptor) signaling: reducing AR activity or removing AR variants that promote tumor growth through RNA interference, CRISPR/Cas9, or editing regulatory elements.
- Restoration of tumor suppressor function: gene transfer of PTEN, p53, or other lost/functionally weakened factors to suppress growth pathways and initiate the cell death cycle. - Direct apoptosis induction: delivery of factors that enhance apoptosis (e.g., BAX, caspases) or by activating the TRAIL/DR-5 pathway.
- Suicide gene therapy and direct hybrid aggression: delivery of prodrug transducer enzymes (e.g., HSV-TK) or tumor-targeted systems that lead to cancer cell death.
- Immunogene therapy: delivery of cytokines (GM-CSF, IL-12) or immune response modulators to convert the tumor into a source of immune attack; genetic modification of T cells or training of the immune system against the tumor.
- Oncolytic viruses and immune-promoting vectors: use of viruses that selectively replicate in cancer cells and carry immunomodulators to induce tumor regression.
- Epigenetic editing: targeted editing or modulation of the epigenetic status of target genes to reactivate tumor suppressors.
- Combination approaches: synergy of genomic therapy with hormonal therapy, PARP inhibitors, immunotherapy, or angiogenesis targets.
Delivery systems and implementation features:
- Vector gene therapy: viral vectors (adenoviruses, lentiviruses, AAV) for delivering genetic material; there are also non-vector approaches (nanoparticles, lipid/polymer carriers).
- Prostate targeting: local delivery (intraprostatic injections), selective infusion, as well as carriers targeting PSMA or other prostate-targeted genes.
- Safety and durability: control of gene expression, prevention of insertional mutations, immunogenic response to vectors, off-target effects.
- Delivery variability: systemic vs. local, expression control (induction/signature-based due to undefined factors).
Advantages and limitations:
- Advantages: targeted effect, possibility of long-term (or repeated) modulation of tumor pathways, potential for combinations.
- Limitations: tumor and microenvironment delivery efficiency, safety of genome editing, risk of immune reactions and unintended effects, regulatory issues.
Development stages and clinical status:
- Mainly in preclinical trials and early clinical phases. Some concepts (e.g., immunogenic gene therapies, viral vectors) are being tested for various types of cancer; for prostate cancer, these ideas are in the early stages and require clinical confirmation.
- Key outcome measures: tumor regression in preclinical models, PSA reduction, radiological regression, survival, and safety.
What's useful to consider in prostate genomic therapy:
- Targeted pathways and specific targets: AR axis, PTEN/PI3K/AKT, p53, RB, DNA damage response (BRCA1/2, ATM/ATR).
- Types of gene therapy: gene delivery vs. genome editing; single-component vs. multicomponent approaches.
- Combinations with existing therapies: hormonal therapy, PARP inhibitors, immunotherapy. - Issues of delivery and regional specificity in the prostate.
- Ethical, regulatory, and safety issues.
7. Synergy of hormonal and genetic therapy for induced regression of prostate adenocarcinoma
The goal of synergistic hormonal and genetic therapy is to combine hormonal therapy (directly suppressing AR signaling—androgen-dependent activity) with genetic approaches that specifically trigger adaptive regression in prostate adenocarcinoma cells. The goal is to enhance tumor cell death, reduce resistance to hormonal therapy, and lead to more durable remission. Synergetic strategy:
- Most prostate adenocarcinomas are dependent on AR signaling. When it is suppressed, the tumor partially regresses, but resistance and clusters of AR-independent cells develop.
- A combination of hormonal therapy and genetic approaches can "kick" the tumor into a different regression state by activating programmed cell death, enhancing apoptosis, or restoring cellular regulation (e.g., correcting abnormalities in the Apoptosis-RAI pathway or DDR). Genetic targets and approaches (approximate spectrum):
- Suppression of the AR pathway and its regulators at the genetic level: knockout of AR or coactivators (e.g., SRC/NRIP1, etc.), blocking AR variants (AR-V7) using genetic tools.
- Restoration of tumor suppressor gene function: TP53, RB1, PTEN – to enhance cell sensitivity to hormonal activity and cell death.
- Direct induction of apoptosis or senescence: introduction of pro-apoptotic genes (BAX, BIM) or senescence factors under the control of genetic switches.
- Modulation of the DNA repair program: targeting the ATM/ATR, BRCA1/2, and PARP pathways (e.g., combination with PARP inhibitors can be enhanced with appropriate genetic correction).
- Immunotraining and cell "immunogenicity": genetic expression of factors that stimulate the immune response (GM-CSF, IL-12, etc.) to reactivate anti-tumor immunity after hormonal stress.
Vectorization and regulatory mechanisms:
- Vectors: viral (AAV, lentanvirus, adeno-pancryogenetic constructs) and non-viral delivery systems; the choice depends on the required specificity and duration of expression.
- Expression control: inducible promoters (e.g., Tet-On/On), hormone-responsive elements (AR-defined promoters, e.g., PSA-like elements), or "two-factor" combinations (e.g., hormonal regulation plus a drug-dependent system) to increase selectivity.
- Pro-payload ideas: pro-apoptotic genes, retro- or retriever copies of TP53/PTEN, vaccinin or immunomodulators, "surrogate" selective genes that are activated only in cells with a specific AR activity profile.
Potential application schemes (conceptual):
- Simultaneous strategy: hormonal therapy reduces AR signaling, and gene therapy induces regression through apoptosis/senescence in the remaining cells; AR-independent gene expression control (e.g., Tet-On) can be used for precise regulation.
- Sequential strategy: first, hormonal therapy reduces AR activity, then introduces a genetic module that triggers cell death or restores regulation to capture resident tumor cells after AR suppression.
- Multi-target strategy: combines AR signaling modification and simultaneous DDR/apoptosis modulation to minimize resistance.
Benefits and mechanistic logic of synergy:
- Resistance reduction: ablation of AR-dependent pathways combined with activation of the cell death "script" can reduce the chances of tumors developing resistant phenotypes.
- Immunotherapeutic potential: stress- and immunogenic signaling modifications following hormone deprivation can enhance anti-tumor immunization.
- Potential for more precise selectivity: the use of hormonally targeted regulators or inducers allows for restriction of gene module expression by prostate tumor cells.
Key issues and challenges:
- Delivery and specificity: efficient delivery of genetic payloads to prostate tumors without significant distribution to normal tissues; avoidance of off-target effects.
- Control of expression: the need for precise control of timing and expression levels to avoid toxicity and resistance.
- Continuity of resistance: tumors can adapt to both modalities; a multi-modal targeting strategy is needed.
- Safety and regulatory: risks associated with genetic vectors (insertional mutagenesis, immune response), long-term consequences of gene expression.
- Models and preclinical design: robust models (DU145, LNCaP, 22Rv1 cell lines; PZD models, rabbit/mouse models) are needed to test selectivity and efficacy.
Development steps to consider:
- Target and regulatory design: determine which genetic modules will be AR-dependent or AR-independent to ensure regression even with AR pathway modifications.
- Vector platform and control system: select a suitable vector, define a control system (inducible vs. constant expression) to ensure tissue specificity.
- Preclinical modeling: in vitro testing on different lines (AR+, AR- variants, PTEN/TP53 status) and in vivo testing in KB-PDX mouse models or human xenografts.
- Ethical and regulatory plans: ongoing safety monitoring, pre-planned clinical-experimental pathways.
With advances in high-throughput epigenomic approaches, visualizing chromatin structures and how their changes lead to disease development and progression has become an increasingly sought-after area of research. Chromatin remodeling from a condensed state to a transcription-friendly state allows DNA-binding proteins to access DNA and control gene expression. Chromatin remodeling is a promising avenue for therapeutic approaches to prostate cancer. ChromoGen technology can investigate how DNA mutations alter chromatin structure, linking this to disease and hormonal genetic conditions activating induced regression of prostate adenocarcinoma [15].
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
I would like to offer my testimony in the support. I have received through the peer review process and support the editorial office where they are to support young authors like me, encourage them to publish their work in your esteemed journals, and globalize and share knowledge globally. I really appreciate your journal, peer review, and editorial office.
Dear Agrippa Hilda- Editorial Coordinator of Journal of Neuroscience and Neurological Surgery, "The peer review process was very quick and of high quality, which can also be seen in the articles in the journal. The collaboration with the editorial office was very good."
I would like to express my sincere gratitude for the support and efficiency provided by the editorial office throughout the publication process of my article, “Delayed Vulvar Metastases from Rectal Carcinoma: A Case Report.” I greatly appreciate the assistance and guidance I received from your team, which made the entire process smooth and efficient. The peer review process was thorough and constructive, contributing to the overall quality of the final article. I am very grateful for the high level of professionalism and commitment shown by the editorial staff, and I look forward to maintaining a long-term collaboration with the International Journal of Clinical Case Reports and Reviews.
To Dear Erin Aust, I would like to express my heartfelt appreciation for the opportunity to have my work published in this esteemed journal. The entire publication process was smooth and well-organized, and I am extremely satisfied with the final result. The Editorial Team demonstrated the utmost professionalism, providing prompt and insightful feedback throughout the review process. Their clear communication and constructive suggestions were invaluable in enhancing my manuscript, and their meticulous attention to detail and dedication to quality are truly commendable. Additionally, the support from the Editorial Office was exceptional. From the initial submission to the final publication, I was guided through every step of the process with great care and professionalism. The team's responsiveness and assistance made the entire experience both easy and stress-free. I am also deeply impressed by the quality and reputation of the journal. It is an honor to have my research featured in such a respected publication, and I am confident that it will make a meaningful contribution to the field.
"I am grateful for the opportunity of contributing to [International Journal of Clinical Case Reports and Reviews] and for the rigorous review process that enhances the quality of research published in your esteemed journal. I sincerely appreciate the time and effort of your team who have dedicatedly helped me in improvising changes and modifying my manuscript. The insightful comments and constructive feedback provided have been invaluable in refining and strengthening my work".
I thank the ‘Journal of Clinical Research and Reports’ for accepting this article for publication. This is a rigorously peer reviewed journal which is on all major global scientific data bases. I note the review process was prompt, thorough and professionally critical. It gave us an insight into a number of important scientific/statistical issues. The review prompted us to review the relevant literature again and look at the limitations of the study. The peer reviewers were open, clear in the instructions and the editorial team was very prompt in their communication. This journal certainly publishes quality research articles. I would recommend the journal for any future publications.
Dear Jessica Magne, with gratitude for the joint work. Fast process of receiving and processing the submitted scientific materials in “Clinical Cardiology and Cardiovascular Interventions”. High level of competence of the editors with clear and correct recommendations and ideas for enriching the article.
We found the peer review process quick and positive in its input. The support from the editorial officer has been very agile, always with the intention of improving the article and taking into account our subsequent corrections.
My article, titled 'No Way Out of the Smartphone Epidemic Without Considering the Insights of Brain Research,' has been republished in the International Journal of Clinical Case Reports and Reviews. The review process was seamless and professional, with the editors being both friendly and supportive. I am deeply grateful for their efforts.
To Dear Erin Aust – Editorial Coordinator of Journal of General Medicine and Clinical Practice! I declare that I am absolutely satisfied with your work carried out with great competence in following the manuscript during the various stages from its receipt, during the revision process to the final acceptance for publication. Thank Prof. Elvira Farina
Dear Jessica, and the super professional team of the ‘Clinical Cardiology and Cardiovascular Interventions’ I am sincerely grateful to the coordinated work of the journal team for the no problem with the submission of my manuscript: “Cardiometabolic Disorders in A Pregnant Woman with Severe Preeclampsia on the Background of Morbid Obesity (Case Report).” The review process by 5 experts was fast, and the comments were professional, which made it more specific and academic, and the process of publication and presentation of the article was excellent. I recommend that my colleagues publish articles in this journal, and I am interested in further scientific cooperation. Sincerely and best wishes, Dr. Oleg Golyanovskiy.
Dear Ashley Rosa, Editorial Coordinator of the journal - Psychology and Mental Health Care. " The process of obtaining publication of my article in the Psychology and Mental Health Journal was positive in all areas. The peer review process resulted in a number of valuable comments, the editorial process was collaborative and timely, and the quality of this journal has been quickly noticed, resulting in alternative journals contacting me to publish with them." Warm regards, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. I appreciate the journal (JCCI) editorial office support, the entire team leads were always ready to help, not only on technical front but also on thorough process. Also, I should thank dear reviewers’ attention to detail and creative approach to teach me and bring new insights by their comments. Surely, more discussions and introduction of other hemodynamic devices would provide better prevention and management of shock states. Your efforts and dedication in presenting educational materials in this journal are commendable. Best wishes from, Farahnaz Fallahian.
Dear Maria Emerson, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. I am delighted to have published our manuscript, "Acute Colonic Pseudo-Obstruction (ACPO): A rare but serious complication following caesarean section." I want to thank the editorial team, especially Maria Emerson, for their prompt review of the manuscript, quick responses to queries, and overall support. Yours sincerely Dr. Victor Olagundoye.
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. Many thanks for publishing this manuscript after I lost confidence the editors were most helpful, more than other journals Best wishes from, Susan Anne Smith, PhD. Australian Breastfeeding Association.
Dear Agrippa Hilda, Editorial Coordinator, Journal of Neuroscience and Neurological Surgery. The entire process including article submission, review, revision, and publication was extremely easy. The journal editor was prompt and helpful, and the reviewers contributed to the quality of the paper. Thank you so much! Eric Nussbaum, MD
Dr Hala Al Shaikh This is to acknowledge that the peer review process for the article ’ A Novel Gnrh1 Gene Mutation in Four Omani Male Siblings, Presentation and Management ’ sent to the International Journal of Clinical Case Reports and Reviews was quick and smooth. The editorial office was prompt with easy communication.
Dear Erin Aust, Editorial Coordinator, Journal of General Medicine and Clinical Practice. We are pleased to share our experience with the “Journal of General Medicine and Clinical Practice”, following the successful publication of our article. The peer review process was thorough and constructive, helping to improve the clarity and quality of the manuscript. We are especially thankful to Ms. Erin Aust, the Editorial Coordinator, for her prompt communication and continuous support throughout the process. Her professionalism ensured a smooth and efficient publication experience. The journal upholds high editorial standards, and we highly recommend it to fellow researchers seeking a credible platform for their work. Best wishes By, Dr. Rakhi Mishra.
Dear Jessica Magne, Editorial Coordinator, Clinical Cardiology and Cardiovascular Interventions, Auctores Publishing LLC. The peer review process of the journal of Clinical Cardiology and Cardiovascular Interventions was excellent and fast, as was the support of the editorial office and the quality of the journal. Kind regards Walter F. Riesen Prof. Dr. Dr. h.c. Walter F. Riesen.
Dear Ashley Rosa, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews, Auctores Publishing LLC. Thank you for publishing our article, Exploring Clozapine's Efficacy in Managing Aggression: A Multiple Single-Case Study in Forensic Psychiatry in the international journal of clinical case reports and reviews. We found the peer review process very professional and efficient. The comments were constructive, and the whole process was efficient. On behalf of the co-authors, I would like to thank you for publishing this article. With regards, Dr. Jelle R. Lettinga.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, I would like to express my deep admiration for the exceptional professionalism demonstrated by your journal. I am thoroughly impressed by the speed of the editorial process, the substantive and insightful reviews, and the meticulous preparation of the manuscript for publication. Additionally, I greatly appreciate the courteous and immediate responses from your editorial office to all my inquiries. Best Regards, Dariusz Ziora
Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation, Auctores Publishing LLC, We would like to thank the editorial team for the smooth and high-quality communication leading up to the publication of our article in the Journal of Neurodegeneration and Neurorehabilitation. The reviewers have extensive knowledge in the field, and their relevant questions helped to add value to our publication. Kind regards, Dr. Ravi Shrivastava.
Dear Clarissa Eric, Editorial Coordinator, Journal of Clinical Case Reports and Studies, Auctores Publishing LLC, USA Office: +1-(302)-520-2644. I would like to express my sincere appreciation for the efficient and professional handling of my case report by the ‘Journal of Clinical Case Reports and Studies’. The peer review process was not only fast but also highly constructive—the reviewers’ comments were clear, relevant, and greatly helped me improve the quality and clarity of my manuscript. I also received excellent support from the editorial office throughout the process. Communication was smooth and timely, and I felt well guided at every stage, from submission to publication. The overall quality and rigor of the journal are truly commendable. I am pleased to have published my work with Journal of Clinical Case Reports and Studies, and I look forward to future opportunities for collaboration. Sincerely, Aline Tollet, UCLouvain.
Dear Ms. Mayra Duenas, Editorial Coordinator, International Journal of Clinical Case Reports and Reviews. “The International Journal of Clinical Case Reports and Reviews represented the “ideal house” to share with the research community a first experience with the use of the Simeox device for speech rehabilitation. High scientific reputation and attractive website communication were first determinants for the selection of this Journal, and the following submission process exceeded expectations: fast but highly professional peer review, great support by the editorial office, elegant graphic layout. Exactly what a dynamic research team - also composed by allied professionals - needs!" From, Chiara Beccaluva, PT - Italy.
Dear Maria Emerson, Editorial Coordinator, we have deeply appreciated the professionalism demonstrated by the International Journal of Clinical Case Reports and Reviews. The reviewers have extensive knowledge of our field and have been very efficient and fast in supporting the process. I am really looking forward to further collaboration. Thanks. Best regards, Dr. Claudio Ligresti
Dear Chrystine Mejia, Editorial Coordinator, Journal of Neurodegeneration and Neurorehabilitation. “The peer review process was efficient and constructive, and the editorial office provided excellent communication and support throughout. The journal ensures scientific rigor and high editorial standards, while also offering a smooth and timely publication process. We sincerely appreciate the work of the editorial team in facilitating the dissemination of innovative approaches such as the Bonori Method.” Best regards, Dr. Matteo Bonori.
I recommend without hesitation submitting relevant papers on medical decision making to the International Journal of Clinical Case Reports and Reviews. I am very grateful to the editorial staff. Maria Emerson was a pleasure to communicate with. The time from submission to publication was an extremely short 3 weeks. The editorial staff submitted the paper to three reviewers. Two of the reviewers commented positively on the value of publishing the paper. The editorial staff quickly recognized the third reviewer’s comments as an unjust attempt to reject the paper. I revised the paper as recommended by the first two reviewers.
Dear Maria Emerson, Editorial Coordinator, Journal of Clinical Research and Reports. Thank you for publishing our case report: "Clinical Case of Effective Fetal Stem Cells Treatment in a Patient with Autism Spectrum Disorder" within the "Journal of Clinical Research and Reports" being submitted by the team of EmCell doctors from Kyiv, Ukraine. We much appreciate a professional and transparent peer-review process from Auctores. All research Doctors are so grateful to your Editorial Office and Auctores Publishing support! I amiably wish our article publication maintained a top quality of your International Scientific Journal. My best wishes for a prosperity of the Journal of Clinical Research and Reports. Hope our scientific relationship and cooperation will remain long lasting. Thank you very much indeed. Kind regards, Dr. Andriy Sinelnyk Cell Therapy Center EmCell
Dear Editorial Team, Clinical Cardiology and Cardiovascular Interventions. It was truly a rewarding experience to work with the journal “Clinical Cardiology and Cardiovascular Interventions”. The peer review process was insightful and encouraging, helping us refine our work to a higher standard. The editorial office offered exceptional support with prompt and thoughtful communication. I highly value the journal’s role in promoting scientific advancement and am honored to be part of it. Best regards, Meng-Jou Lee, MD, Department of Anesthesiology, National Taiwan University Hospital.
Dear Editorial Team, Journal-Clinical Cardiology and Cardiovascular Interventions, “Publishing my article with Clinical Cardiology and Cardiovascular Interventions has been a highly positive experience. The peer-review process was rigorous yet supportive, offering valuable feedback that strengthened my work. The editorial team demonstrated exceptional professionalism, prompt communication, and a genuine commitment to maintaining the highest scientific standards. I am very pleased with the publication quality and proud to be associated with such a reputable journal.” Warm regards, Dr. Mahmoud Kamal Moustafa Ahmed
Dear Maria Emerson, Editorial Coordinator of ‘International Journal of Clinical Case Reports and Reviews’, I appreciate the opportunity to publish my article with your journal. The editorial office provided clear communication during the submission and review process, and I found the overall experience professional and constructive. Best regards, Elena Salvatore.
Dear Mayra Duenas, Editorial Coordinator of ‘International Journal of Clinical Case Reports and Reviews Herewith I confirm an optimal peer review process and a great support of the editorial office of the present journal
Dear Editorial Team, Clinical Cardiology and Cardiovascular Interventions. I am really grateful for the peers review; their feedback gave me the opportunity to reflect on the message and impact of my work and to ameliorate the article. The editors did a great job in addition by encouraging me to continue with the process of publishing.
Dear Cecilia Lilly, Editorial Coordinator, Endocrinology and Disorders, Thank you so much for your quick response regarding reviewing and all process till publishing our manuscript entitled: Prevalence of Pre-Diabetes and its Associated Risk Factors Among Nile College Students, Sudan. Best regards, Dr Mamoun Magzoub.
